Luis Paz-Ares
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Heinhuis K, Schilder R, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Britschgi C, Paz-Ares L, Carlino M, Jörger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord J, Siu L. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. JAMA Oncol 2019:1-8.
Nov 7, 2019Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Nov 7, 2019JAMA Oncol 2019:1-8
Heinhuis Kimberley M, Schilder Russell J, O'Byrne Kenneth, Curigliano Giuseppe, Romano Emanuela, Patah Poliana, Wang Rui, Liu Yali, Bajaj Gaurav, Britschgi Christian, Paz-Ares Luis, Carlino Matteo, Jörger Markus, Di Nicola Massimo, Meniawy Tarek, Rottey Sylvie, Moreno Victor, Gazzah Anas, Delord Jean-Pierre, Siu Lillian L
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Peters S, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd F, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Früh M, Ho C, Gettinger S, Johnson M, Jänne P, Garassino M, Christoph D, Toh C, Rizvi N, Chaft J, Carcereny Costa E, Patel J, Chow L, Koczywas M, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol 2017; 35:2781-2789.
Jun 13, 2017Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Jun 13, 2017J Clin Oncol 2017; 35:2781-2789
Peters Solange, van den Heuvel Michel, Rothenstein Jeffrey, Reck Martin, Paz-Ares Luis, Shepherd Frances A, Kurata Takayasu, Li Zhengrong, Qiu Jiaheng, Kowanetz Marcin, Mocci Simonetta, Shankar Geetha, Sandler Alan, Früh Martin, Ho Cheryl, Gettinger Scott, Johnson Melissa L, Jänne Pasi A, Garassino Marina C, Christoph Daniel, Toh Chee Keong, Rizvi Naiyer A, Chaft Jamie E, Carcereny Costa Enric, Patel Jyoti D, Chow Laura Q M, Koczywas Marianna, Felip Enriqueta
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II
Kisbenedek L, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof G, Paz-Ares L, Pizzocaro G, Mead G, Mason M, Klepp O, Kliesch S, Koehrmann K, Kollmannsberger C, Kuczyk M, Laguna P, Galvis O, Loy V, Pont J, Pottek T, Powles T, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, Skakkebaek N, Sedlmayer F, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz H, Schmidberger H, Schmoll H, Schrader M, von der Maase H, Jones W, Krege S, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder P, De Santis M, de Wit M, de Wit R, Classen J, Cavallin-Ståhl E, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Derigs H, Dieckmann K, Dieing A, Gillessen Sommer S, Hartmann J, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Germa-Lluch J, Gerl A, Droz J, Fenner M, Fizazi K, Flechon A, Fosså S, del Muro X, Gauler T, Geczi L, Joffe J. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. European urology 2008; 53:497-513.
Mar 1, 2008European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II
Mar 1, 2008European urology 2008; 53:497-513
Kisbenedek László, Mueller Rolf, Nichols Craig, Nicolai Nicola, Oliver Tim, Ondrus Dalibor, Oosterhof Gosse O N, Paz-Ares Luis, Pizzocaro Giorgio, Mead Graham M, Mason Malcolm D, Klepp Olbjørn, Kliesch Sabine, Koehrmann Kai Uwe, Kollmannsberger Christian, Kuczyk Markus, Laguna Pilar, Galvis Oscar Leiva, Loy Volker, Pont Jörg, Pottek Tobias, Powles Tom, Sohaib Aslam, Tjulandin Sergei, Warde Padraig, Weinknecht Stefan, Weissbach Lothar, Wittekind Christian, Winter Eva, Wood Lori, Skakkebaek Niels E, Sedlmayer Felix, Rick Oliver, Rosti Giovanni, Salvioni Roberto, Scheiderbauer Jutta, Schmelz Hans-Ulrich, Schmidberger Heinz, Schmoll Hans-Joachim, Schrader Mark, von der Maase Hans, Jones William G, Krege Susanne, Clemm Christoph, Cohn-Cedermark Gabriella, Culine Stéphane, Daugaard Gedske, De Mulder Pieter H M, De Santis Maria, de Wit Maike, de Wit Ronald, Classen Johannes, Cavallin-Ståhl Eva, Beyer Jörg, Souchon Rainer, Albers Peter, Albrecht Walter, Algaba Ferran, Bamberg Michael, Bodrogi István, Bokemeyer Carsten, Derigs Hans Günter, Dieckmann Klaus-Peter, Dieing Annette, Gillessen Sommer Silke, Hartmann Jörg T, Hartmann Michael, Heidenreich Axel, Hoeltl Wolfgang, Horwich Alan, Huddart Robert, Jewett Michael, Germa-Lluch Jose Ramon, Gerl Arthur, Droz Jean-Pierre, Fenner Martin, Fizazi Karim, Flechon Aude, Fosså Sophie D, del Muro Xavier Garcia, Gauler Thomas, Geczi Lajos, Joffe Johnathan